Janoshik 99%+Retatrutide
Triple-agonist peptide studied across three receptor systems.
Discount applies to the quantity of this product in your cart.
Mechanism of action — research context
Retatrutide is studied as a next-generation metabolic peptide activating three receptors: GLP-1, GIP, and glucagon. This triple-agonist mechanism is investigated for appetite pathways, energy expenditure, and fat-oxidation signaling, with glucagon-pathway stimulation a particular focus in body-composition research.
Frequently asked questions
Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide engineered as a triple agonist — it engages the GLP-1, GIP, and glucagon receptors from a single molecule, rather than one or two receptors like earlier incretin-class compounds.
It's used as a reference standard for triple-receptor metabolic research — appetite-pathway signaling, energy expenditure, and fat-oxidation studies, with particular interest in whether engaging all three receptors together produces effects beyond dual-agonist compounds.
Each batch is analyzed by RP-HPLC for purity and mass spectrometry for identity confirmation, with results published on an independent, batch-specific certificate of analysis from Janoshik.
As a lyophilized powder, it ships cold-chain and should be kept refrigerated (or frozen for longer-term storage) until reconstitution; once reconstituted for laboratory use, refrigerate and use within the compound's stability window rather than storing indefinitely at room temperature.